Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Rev Neurosci ; 22(6): 625-45, 2011.
Article in English | MEDLINE | ID: mdl-22103308

ABSTRACT

Disturbances of dopaminergic neurotransmission may be caused by changes in concentrations of synaptic dopamine (DA) and/or availabilities of pre- and post-synaptic transporter and receptor binding sites. We present a series of experiments which focus on the regulatory mechanisms of the dopamin(DA)ergic synapse in the rat striatum. In these studies, DA transporter (DAT) and/or D(2) receptor binding were assessed with either small animal single-photon emission computed tomography (SPECT) or positron emission tomography (PET) after pharmacological challenge with haloperidol, L-DOPA and methylphenidate, and after nigrostriatal 6-hydroxydopamine lesion. Investigations of DAT binding were performed with [(123)I]N-ω-fluoropropyl-2ß-carbomethoxy-3ß-(4-iodophenyl)nortropane ([(123)I]FP-CIT). D(2) receptor bindingd was assessed with either [(123)I](S)-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide ([(123)I]IBZM) or [(18)F]1[3-(4'fluorobenzoyl)propyl]-4-(2-keto-3-methyl-1-benzimidazolinyl)piperidine ([(18)F]FMB). Findings demonstrate that in vivo investigations of transporter and/or receptor binding are feasible with small animal SPECT and PET. Therefore, tracers that are radiolabeled with isotopes of comparatively long half-lives such as (123)I may be employed. Our approach to quantify DAT and/or D(2) receptor binding at baseline and after pharmacological interventions inducing DAT blockade, D(2) receptor blockade, and increases or decreases of endogenous DA concentrations holds promise for the in vivo assessment of synaptic function. This pertains to animal models of diseases associated with pre- or postsynaptic DAergic deficiencies such as Parkinson's disease, Huntington's disease, attention-deficit/hyperactivity disorder, schizophrenia or drug abuse.


Subject(s)
Corpus Striatum , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine/metabolism , Positron-Emission Tomography , Synapses/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Adrenergic Agents/toxicity , Animals , Benzamides/pharmacokinetics , Brain Mapping , Corpus Striatum/cytology , Corpus Striatum/diagnostic imaging , Corpus Striatum/drug effects , Dopamine Agents/pharmacology , Dose-Response Relationship, Drug , Male , Mesylates/pharmacokinetics , Oxidopamine/toxicity , Protein Binding/drug effects , Pyrrolidines/pharmacokinetics , Rats , Synapses/drug effects , Tropanes/pharmacokinetics
2.
Neurobiol Learn Mem ; 95(1): 37-45, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20955808

ABSTRACT

Excitation of the mesocorticolimbic pathway, originating from dopaminergic neurons in the ventral tegmental area (VTA), may be important for the development of exaggerated fear responding. Among the forebrain regions innervated by this pathway, the amygdala is an essential component of the neural circuitry of conditioned fear. The functional role of the dopaminergic pathway connecting the VTA to the basolateral amygdala (BLA) in fear and anxiety has received little attention. In vivo microdialysis was performed to measure dopamine levels in the BLA of Wistar rats that received the dopamine D(2) agonist quinpirole (1 µg/0.2 µl) into the VTA and were subjected to a fear conditioning test using a light as the conditioned stimulus (CS). The effects of intra-BLA injections of the D(1) antagonist SCH 23390 (1 and 2 µg/0.2 µl) and D(2) antagonist sulpiride (1 and 2 µg/0.2 µl) on fear-potentiated startle (FPS) to a light-CS were also assessed. Locomotor performance was evaluated by use of open-field and rotarod tests. Freezing and increased dopamine levels in the BLA in response to the CS were both inhibited by intra-VTA quinpirole. Whereas intra-BLA SCH 23390 did not affect FPS, intra-BLA sulpiride (2 µg) inhibited FPS. Sulpiride's ability to decrease FPS cannot be attributed to nonspecific effects because this drug did not affect motor performance. These findings indicate that the dopamine D(2) receptor pathway connecting the ventral tegmental area and the basolateral amygdala modulates fear and anxiety and may be a novel pharmacological target for the treatment of anxiety.


Subject(s)
Amygdala/physiology , Conditioning, Psychological/physiology , Dopamine/physiology , Fear/physiology , Receptors, Dopamine D2/physiology , Ventral Tegmental Area/physiology , Amygdala/drug effects , Analysis of Variance , Animals , Benzazepines/pharmacology , Chromatography, High Pressure Liquid , Conditioning, Psychological/drug effects , Dopamine Antagonists/pharmacology , Fear/drug effects , Freezing Reaction, Cataleptic/physiology , Male , Microdialysis , Microinjections , Motor Activity/drug effects , Motor Activity/physiology , Rats , Rats, Wistar , Reflex, Startle/drug effects , Reflex, Startle/physiology , Rotarod Performance Test , Sulpiride/pharmacology , Ventral Tegmental Area/drug effects
4.
Ribeirão Preto; s.n; 1994. 63 p.
Thesis in Portuguese | Index Psychology - Theses | ID: pte-27058

ABSTRACT

Foi investigado o papel de diferentes núcleos da amígdala na modulação do efeito amnéstico de drogas ansiolíticas. Os animais receberam microinjeção de benzodiazepinas ou do antagonista 5ht3 - brl 46 47oa e foram treinados num teste de esquiva inibitória. Foi observado que o núcleo basolateral tem um importante papel (AU)

SELECTION OF CITATIONS
SEARCH DETAIL
...